Gilead Sciences

J.P. Morgan is out with its report today on Gilead Sciences (NASDAQ: GILD), maintaining Overweight. In a note to clients, J.P. Morgan writes, "Overall, we found 1Q results disappointing with uncertainty around the HIV business. That said, there are major pipeline events that are less than three...

Citigroup has raised the price target on Gilead Sciences (NASDAQ: GILD) from $43 to $44 and maintains its Hold rating.

J.P. Morgan is out with its report today on Gilead Sciences (NASDAQ: GILD), maintaining Overweight. In a note to clients, J.P. Morgan writes, "Our 1Q11 total product sales forecasts are ahead of street at $1,942M (cons: $1,917M). Gilead remains our top pick for 2011 and we continue to recommend...

According to Wedbush, it is dropping coverage of Gilead Sciences (NASDAQ: GILD) due to analyst departure. Wedbush reported that, effective upon termination of coverage, the last recommendation (UNDERPERFORM), estimates and price target issued for the company should not be relied upon going forward...

Deutsche Bank has issued a report on Gilead Sciences (NASDAQ: GILD) weekly IMS. According to the report, "Analysis of IMS weekly scrips for the 11th week of 1Q indicates that GILD's HIV franchise is tracking above street consensus estimates. Overall scrip trends suggest a $37.2M higher HIV sales...

In a report published by Deutsche Bank, the FDA meta-analysis on abacavir will not change much for Gilead Sciences (NASDAQ: GILD). Deutsche Bank reported that yesterday, a FDA meta-analysis of risk of myocardial infarction (MI) associated with abacavir was presented at CROI '11. “Recall, abacavir (...

According to Deutsche Bank, analysis of the IMS weekly scrips for the 7th week of 1Q indicates that Gilead Sciences (NASDAQ: GILD) HIV franchise is tracking above street consensus estimates. Deutsche Bank reported that that overall scrip trends suggest a $29.5M increase in HIV sales vs. street...

Gilead Sciences, Inc. (NASDAQ: GILD) announced that a Phase 3 trial of its integrase inhibitor elivitegravir will remain blinded for 96 rather than 48 weeks, following an FDA request. GILD suggests the request neither indicates an Agency safety concern nor will it delay filing for the Quad pill,...

Wells Fargo is resuming coverage of Gilead Sciences, Inc. (NASDAQ: GILD) with a change in analyst, an Outperform rating on the shares, and a $48-52 valuation range. “We held extensive discussions with managed care providers covering a total of 70 million lives (more than one-fifth of the U.S....

Gilead Sciences, Inc. (NASDAQ: GILD) plans to announce 3Q10 results on October 19, Jefferies & Company reports. “IMS data suggest HIV franchise sales should be in-line with our slightly-below consensus estimates for the quarter,” Jefferies & Company writes. “We are lowering outer year...

Gilead Sciences, Inc. (Nasdaq: GILD) announced on Tuesday that the U.S. Food and Drug Administration has approved Cayston, an inhaled treatment for respiratory symptoms in cystic-fibrosis patients with pseudomonas aeruginosa, for marketing. Cayston, with the generic name of aztreonam, was approved...